vTv Therapeutics sells Reneo shares for $4.4M to fund cadisegliatin Phase 3

vTv Therapeutics Inc.

Sold all Reneo common shares held under 2017 license for ~$4.4M gross proceeds.
Proceeds support preparations for launch of cadisegliatin Phase 3 in type 1 diabetes.
Remains eligible for up to $94.5M in clinical, regulatory & commercial milestones.
Eligible for tiered royalties (mid-single to low teens) on potential net sales of mavodelpar.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

vTv Therapeutics Inc. entered into Common Stock Repurchase Agreement with Reneo Pharmaceuticals, Inc. valued at approximately $4.4 million (effective 2023-10-30).

Action: entry
Agreement: equity purchase
Counterparty: Reneo Pharmaceuticals, Inc.
Value: approximately $4.4 million
Effective: 2023-10-30

Exact text from the filing

On October 30, 2023, vTv Therapeutics LLC (“vTv LLC”), the principal operating subsidiary of vTv Therapeutics, Inc. (the “Company”) entered into a Common Stock Repurchase Agreement (the "Repurchase Agreement") with Reneo Pharmaceuticals, Inc. (“Reneo”) pursuant to which Reneo agreed to purchase all shares of common stock of Reneo that had been owned by vTv LLC. Pursuant to the Repurchase Agreement, Reneo agreed to pay vTv LLC gross proceeds of approximately $4.4 million for the Reneo common stock.

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

vTv Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001641489-23-000062

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.